Malaria immunogen and vaccine

a technology of immunogen and malaria, applied in the field of immunogen and vaccine, can solve the problems of not being able to effectively fight any form of malaria, being less attractive to the immediate needs of travelers and the military, and unable to use them as vaccines in vitro, etc., and achieves the effect of high antibody titers, easy preparation, and high antibody titers
US20050208068A1Inactive Publication Date: 2005-09-22MILICH DAVID +1
1 Cites 22 Cited by

Patent Information

Authority / Receiving Office
US · United States
Patent Type
Applications(United States)
Current Assignee / Owner
MILICH DAVID
Publication Date
2005-09-22
Estimated Expiration
Not applicable · inactive patent

Smart Images

  • Figure 1
    Figure 1
  • Figure 2
    Figure 2
  • Figure 3
    Figure 3
Patent Text Reader

Abstract

A chimeric, carboxy-terminal truncated hepatitis B virus nucleocapsid protein (HBc) is disclosed that contains an immunogen for inducing the production of antibodies to malarial proteins. An immunogenic malarial epitope is expressed between residues 78 and 79 of the HBc immunogenic loop sequence. The chimer preferably contains a malaria-specific T cell epitope and is preferably engineered for both enhanced stability of self-assembled particles and enhanced yield of those chimeric particles. Methods of making and using the chimers are also disclosed.
Need to check novelty before this filing date? Find Prior Art

Description

CROSS-REFERENCE TO RELATED APPLICATION

[0001] This is a continuation-in-part of application Ser. No. 60 / 225,813, filed Aug. 16, 2000, whose disclosures are incorporated herein by reference.TECHNICAL FIELD

[0002] The present invention relates to the intersection of the fields of immunology and protein engineering, and particularly to an immunogen and vaccine useful in prevention of malaria infection by P. falciparum or P. vivax. BACKGROUND OF THE INVENTION

[0003] Malaria is by far the world's most important tropical parasitic disease, killing more people than any other communicable disease, with the exception of tuberculosis. The causative agents in humans are four species of Plasmodium protozoa: P. falciparum, P. vivax, P. ovale and P. malariae. Although P. falciparum accounts for the majority of infections and is responsible for the vast majority of deaths attributable to malaria, P. vivax causes a recurring chronic debilitating disease for which a vaccine is necessary.

[0004] Mala...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More